Their relationship is still going strong. Patrick Mahomes and Travis Kelce said that it was 'a great honor' for the president ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

We expect Lilly to continue to grow faster than the market, and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new ...

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease seve ...

Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Surgical tweaks for “Ozempic face” are on the rise. The latest report from AAFPRS reveals a 50% increase in facial fat ...

"Palatin concludes Phase II trial of combination therapy for obesity" was originally created and published by Clinical Trials ...

President Trump’s proposed tariffs on Denmark could have costly consequences for Americans relying on GLP-1 medications like ...